| Bioactivity | LUNA18 is an orally active KRAS inhibitor with an IC50 of ＜2 nM against KRASG12D-SOS. LUNA18 can be used for the research of cancer[1]. |
| Target | IC50: ＜2 nM (KRASG12D-SOS)0.043 nM (KRASG12D) |
| Name | LUNA18 |
| CAS | 2676177-63-0 |
| Formula | C73H105F5N12O12 |
| Molar Mass | 1437.68 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tanada M, et al. Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor. J Am Chem Soc. 2023 Aug 2;145(30):16610-16620. |
LUNA18
CAS: 2676177-63-0 F: C73H105F5N12O12 W: 1437.68
LUNA18 is an orally active KRAS inhibitor with an IC50 of ＜2 nM against KRASG12D-SOS. LUNA18 can be used for the resear
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.